替加环素治疗危重患者多重耐药菌感染的临床效果及不良反应发生率分析  

Clinical efficacy and adverse reactions of tegafycline in the treatment of multidrug-resistant bacterial infections in critically ill patients

作　　者：杨双嘉 邝敏[1] 黄丽沙 庞辛欣 Yang Shuangjia;Kuang Min;Huang Lisa;Pang Xinxin(Department of Respiratory,the Second People's Hospital of Nanning City 530031)

机构地区：[1]南宁市第二人民医院呼吸内科,530031

出　　处：《中国社区医师》2018年第23期54-54,56,共2页Chinese Community Doctors

摘　　要：目的:探讨替加环素治疗危重患者多重耐药菌感染的成效。方法:收治严重肺部感染患者12例,随机分为观察组和对照组,各6例。对照组应用头孢哌酮-舒巴坦治疗,观察组应用替加环素治疗。结果:观察组治疗总疗效明显高于对照组(P<0.05)。观察组不良反应发生率低于对照组(P<0.05)。结论:替加环素可有效提升危重患者多重耐药菌感染的治疗成效,降低并发症的发生率。Objective:To investigate the efficacy of tegafur in the treatment of multidrug-resistant bacterial infections in critically ill patients.Methods:12 patients with severe pulmonary infection were randomly divided into the observation group and the control group,with 6 cases in each group.The control group were treated with cefoperazone sulbactam,while the observation group were treated with tegafycline.Results:The total efficacy of the observation group was significantly higher than that of the control group(P<0.05);the incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:Tegafycline can effectively enhance the efficacy of multidrug-resistant bacterial infections in critically ill patients and reduce the incidence of complications.

关 键 词：多重耐药菌感染 替加环素 危重患者 安全性 

分 类 号：R969[医药卫生—药理学]